OBJECTIVES: Aortic valve stenosis (AS) causes cardiac fibrosis and left ventricular hypertrophy, and over time heart failure can occur. To date, a reliable marker to predict progression of AS or the development of heart failure is still lacking. In this study, we addressed the hypothesis that fibulin-1 levels reflect myocardial fibrosis. METHODS: Patients undergoing heart surgery at the Odense University were investigated. By 2012 data on outcome were obtained. RESULTS: In 293 patients, plasma fibulin-1 levels were measured. Patients with AS or atrial fibrillation (AF) had significantly higher fibulin-1 levels compared to those with coronary artery disease only (p = 0.005). Patients with preoperatively diagnosed chronic AF had significantly higher levels of fibulin-1 compared to those without (p = 0.004). Plasma fibulin-1 levels showed no relationship to echocardiographic size and had no impact on outcome, death or other adverse events. CONCLUSION: This study shows that plasma fibulin-1 levels are increased in patients with AS and AF compared to patients with coronary disease only. Our study results suggest fibulin-1, a vascular extracellular matrix (ECM) protein, as a marker of ECM turnover perhaps due to the increased myocardial stretch that is related to pressure overload.
OBJECTIVES:Aortic valve stenosis (AS) causes cardiac fibrosis and left ventricular hypertrophy, and over time heart failure can occur. To date, a reliable marker to predict progression of AS or the development of heart failure is still lacking. In this study, we addressed the hypothesis that fibulin-1 levels reflect myocardial fibrosis. METHODS:Patients undergoing heart surgery at the Odense University were investigated. By 2012 data on outcome were obtained. RESULTS: In 293 patients, plasma fibulin-1 levels were measured. Patients with AS or atrial fibrillation (AF) had significantly higher fibulin-1 levels compared to those with coronary artery disease only (p = 0.005). Patients with preoperatively diagnosed chronic AF had significantly higher levels of fibulin-1 compared to those without (p = 0.004). Plasma fibulin-1 levels showed no relationship to echocardiographic size and had no impact on outcome, death or other adverse events. CONCLUSION: This study shows that plasma fibulin-1 levels are increased in patients with AS and AF compared to patients with coronary disease only. Our study results suggest fibulin-1, a vascular extracellular matrix (ECM) protein, as a marker of ECM turnover perhaps due to the increased myocardial stretch that is related to pressure overload.
Authors: Pernille Holmager; Michael Egstrup; Ida Gustafsson; Morten Schou; Jordi S Dahl; Lars Melholt Rasmussen; Jacob E Møller; Christian Tuxen; Jens Faber; Caroline Kistorp Journal: BMC Cardiovasc Disord Date: 2017-01-10 Impact factor: 2.298
Authors: Mariana Fragão-Marques; I Miranda; D Martins; I Barroso; C Mendes; A Pereira-Neves; I Falcão-Pires; A Leite-Moreira Journal: BMC Cardiovasc Disord Date: 2020-10-31 Impact factor: 2.298